Amphastar Pharmaceuticals (AMPH) FY2019 results: revenue $322 million, up 9.4% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $322 million for fiscal 2019, the year ended 31 December 2019, up 9.4% on the year before. Net income was $49 million, and diluted earnings per share $0.98. The figures are the company's own, from the 10-K it filed with the SEC on 16 March 2020.
Revenue
$322 million
+9.4% on the year
FY2012FY2019
Operating margin
-0.0%
-2.9% a year earlier
FY2012FY2019
Net income
$49 million
FY2012FY2019
Diluted EPS
$0.98
FY2012FY2019
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Revenue
322
295
240
+9.4%
Cost of revenue
190
188
149
+1.5%
Gross profit
132
107
90.5
+23.3%
Gross margin
40.9%
36.3%
37.7%
Research and development
68.9
57.6
43.5
+19.6%
Operating income
-0.0
-8.6
-1.3
Operating margin
-0.0%
-2.9%
-0.5%
Interest expense
0.1
0.2
0.8
-51.0%
Pre-tax income
60.2
-9.9
1.2
Income tax
13.7
-3.3
-2.4
Effective tax rate
22.8%
n/a
-192.0%
Net income
48.9
-5.7
3.6
Net margin
15.2%
-1.9%
1.5%
Diluted EPS
$0.98
-$0.12
$0.09
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Operating cash flow
41.8
38.2
39.2
+9.4%
Capital expenditure
41.6
46.8
35.1
-11.2%
Free cash flow
0.2
-8.6
4.1
Free cash flow margin
0.1%
-2.9%
1.7%
Cash from investing
-50.5
-42.2
-36.9
Cash from financing
-3.8
25.0
-7.7
Depreciation and amortisation
7.1
6.1
6.4
+16.6%
Share-based compensation
17.3
16.7
17.1
+3.7%
Buybacks
22.3
25.0
30.7
-11.0%
Diluted shares, weighted
50m
46m
48m
+7.6%
Shares outstanding at period end
47m
47m
47m
-0.1%
Balance sheet
$ million
FY2019
FY2018
FY2017
On the year
Last 8 years
Shareholders' equity
381
332
334
+14.7%
Non-controlling interest
46.2
31.9
n/a
+44.6%
Debt
46.3
49.1
45.7
-5.6%
Operating lease liabilities
16.3
n/a
n/a
Other liabilities
96.8
100
71.6
-3.3%
Total liabilities and equity
587
514
451
+14.3%
Fixed assets
234
210
181
+11.1%
Goodwill
3.6
4.0
4.5
-8.0%
Intangible assets
8.3
9.1
11.5
-8.8%
Investments
11.7
2.8
2.6
+312.4%
Cash and equivalents
73.7
86.3
65.6
-14.7%
Receivables
45.4
52.2
36.0
-13.0%
Inventory
111
69.3
63.6
+59.4%
Other assets
100.0
79.5
86.8
+25.8%
Total assets
587
514
451
+14.3%
10-K for the year ended 31 December 2019, filed 16 March 2020: the filing.